The global peptide industry is booming, which factory has created a dual benchmark for innovation and cooperation? The answer lies in the Chinese peptide factories that break through with technology and achieve win-win cooperation. With the global peptide market size exceeding 89 billion US dollars by 2025, Chinese peptide factories are becoming the core growth pole of the global health industry through hard core technology and open ecology.

The innovation confidence of Chinese peptide factories comes from ten years of deep cultivation of technology. Top factories have established core technological barriers such as functional resin modification and segmented synthesis of long peptides, breaking through the limitation of 150 amino acid long peptide synthesis. The independently developed cyclic peptide-161 has won the International Innovation Raw Material Award, promoting anti-aging skincare into a new track. By relying on AI targeted screening and green synthesis technology, active peptides with a molecular weight of ≤ 500Da are extracted from natural raw materials such as soybeans and deep-sea fish skins. The absorption rate is as high as 92.5%, and the carbon emissions are reduced to 1/4 of the industry average, achieving a win-win situation of environmental protection and efficiency.

Win win cooperation is the distinctive label of Chinese peptide factories. From the scientific research cooperation between Nanjing Jieti Biotechnology, Oxford University, and BeiGene, to Shandong Jiti Biotechnology becoming the designated global supplier for the inventor of Blue Copper Peptide, Chinese peptide factories have formed a full chain cooperation ecology of "scientific research production application". They not only provide full scale supply from milligrams of scientific research samples to tons of mass production, but also can undertake customized complex modified peptides such as phosphorylation and fluorescent labeling, providing one-stop solutions for fields such as medicine, beauty, and specialty food. Their services cover more than 50 countries and regions around the world.

Nowadays, Chinese peptide factories are no longer just raw material producers. Zhejiang Pai Peptide has entered the core camp of the global GLP-1 receptor agonist supply chain with a research and development investment intensity of over 10%; Hebei Peptide Biotech has built over 40 standardized production lines, becoming a benchmark in the specialty food OEM industry. These factories have established a solid quality foundation with international certification, breaking industry monopolies through continuous innovation, and transforming "Chinese peptides" from technology followers to global industry leaders, injecting strong momentum into the era of precision nutrition.